肝细胞癌患者瑞戈非尼应答相关生物标志物
基于RESORCE试验,分析肝细胞癌患者基线和肿瘤样本,发现5种血浆蛋白低浓度及9种miRNA水平与瑞戈非尼治疗后总生存期延长相关,循环生物标志物和肿瘤遗传特征可能用于筛选瑞戈非尼应答者。
要点
- 基线血浆5种蛋白低浓度与瑞戈非尼治疗后总生存期延长显著相关(校正P≤.05)。
- 9种血浆miRNA水平与瑞戈非尼治疗总生存期显著相关(校正P≤.05)。
- 肿瘤组织测序发现CTNNB1突变见于3/10进展者,VEGFA扩增见于1/7应答者。
核心结论
- 鉴定出与瑞戈非尼治疗后肝细胞癌患者总生存期延长相关的血浆蛋白和miRNA表达模式。
- 这些循环生物标志物和肿瘤遗传特征可能用于识别最可能对瑞戈非尼应答的肝细胞癌患者。
研究设计与样本
- 探索性研究,获取RESORCE试验中接受瑞戈非尼治疗的肝细胞癌患者的存档肿瘤组织和基线血浆样本。
- 499例患者基线血浆分析294种蛋白表达(DiscoveryMAP),349例患者血浆分析750种miRNA水平(miRCURY miRNA PCR)。
- 7例应答者和10例未应答者(进展者)肿瘤组织行二代测序(FoundationOne)。
- 46份肿瘤组织分析770个涉及致癌和炎症通路的基因表达模式(PanCancer Immune Profiling)。
- 采用Cox比例风险模型评估血浆蛋白和miRNA水平与治疗应答(总生存期和至进展时间)的关联。
主要发现
- 266种可评估蛋白中5种(血管生成素1、胱抑素B、转化生长因子β1潜伏相关肽、氧化低密度脂蛋白受体1、C-C基序趋化因子配体3)基线血浆浓度降低与瑞戈非尼治疗后总生存期延长显著相关(校正P≤.05)。
- 这5种蛋白(在炎症和/或肝细胞癌发病机制中起作用)的水平与生存的关联不独立于治疗。
- 499例患者中仅20例水平高且生存时间缩短。
- 血浆甲胎蛋白和c-MET水平与不良结局(总生存期)的关联仅独立于瑞戈非尼治疗。
- 鉴定出9种血浆miRNA(MIR30A、MIR122、MIR125B、MIR200A、MIR374B、MIR15B、MIR107、MIR320、MIR645)水平与瑞戈非尼治疗总生存期显著相关(校正P≤.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In a phase 3 trial (RESORCE), regorafenib increased overall survival compared with placebo in patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. In an exploratory study, we analyzed plasma and tumor samples from study participants to identify genetic, microRNA (miRNA), and protein biomarkers associated with response to regorafenib. METHODS: We obtained archived tumor tissues and baseline plasma samples from patients with HCC given regorafenib in the RESORCE trial. Baseline plasma samples from 499 patients were analyzed for expression of 294 proteins (DiscoveryMAP) and plasma samples from 349 patients were analyzed for levels of 750 miRNAs (miRCURY miRNA PCR). Tumor tissues from 7 responders and 10 patients who did not respond (progressors) were analyzed by next-generation sequencing (FoundationOne). Forty-six tumor tissues were analyzed for expression patterns of 770 genes involved in oncogenic and inflammatory pathways (PanCancer Immune Profiling). Associations between plasma levels of proteins and miRNAs and response to treatment (overall survival and time to progression) were evaluated using a Cox proportional hazards model. RESULTS: Decreased baseline plasma concentrations of 5 of 266 evaluable proteins (angiopoietin 1, cystatin B, the latency-associated peptide of transforming growth factor beta 1, oxidized low-density lipoprotein receptor 1, and C-C motif chemokine ligand 3; adjusted P ≤ .05) were significantly associated with increased overall survival time after regorafenib treatment. Levels of these 5 proteins, which have roles in inflammation and/or HCC pathogenesis, were not associated with survival independently of treatment. Only 20 of 499 patients had high levels and a reduced survival time. Plasma levels of α-fetoprotein and c-MET were associated with poor outcome (overall survival) independently of regorafenib treatment only. We identified 9 plasma miRNAs (MIR30A, MIR122, MIR125B, MIR200A, MIR374B, MIR15B, MIR107, MIR320, and MIR645) whose levels significantly associated with overall survival time with regorafenib (adjusted P ≤ .05). Functional analyses of these miRNAs indicated that their expression level associated with increased overall survival of patients with tumors of the Hoshida S3 subtype. Next-generation sequencing analyses of tumor tissues revealed 49 variants in 27 oncogenes or tumor suppressor genes. Mutations in CTNNB1 were detected in 3 of 10 progressors and VEGFA amplification in 1 of 7 responders. CONCLUSION: We identified expression patterns of plasma proteins and miRNAs that associated with increased overall survival times of patients with HCC following treatment with regorafenib in the RESORCE trial. Levels of these circulating biomarkers and genetic features of tumors might be used to identify patients with HCC most likely to respond to regorafenib. ClinicalTrials.gov number NCT01774344. NCBI GEO accession numbers: mRNA data (NanoString): GSE119220; miRNA data (Exiqon): GSE119221.
引用
- Teufel M, Seidel H, Köchert K, et al. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology. 2019. PMID: 30738047. doi:10.1053/j.gastro.2019.01.261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。